Smith & Nephew (NYSE: SNN) Selected to Develop New Technology for Treating Battlefield Injuries

Rochester, New York 11/20/2009 09:45 PM GMT (TransWorldNews)

Smith & Nephew ( NYSE: SNN, LSE: SN) signed a technology development contract with the United States Department of Defense to develop a "Fracture putty" system to improve standard of care for injured soldiers is the ultimate revolutionized technology for our military wounded. This technology may lead to the creation of a fracture fixation system intended to revolutionize the treatment of the limbs of soldiers who sustain battlefield injuries.

TryPennyStocks, a leading financial publication, is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter

Last year, the Defense Advanced Research Projects Agency (DARPA), the central research and development agency for the U.S. Department of Defense, accepted proposals to create and develop "fracture putty," a dynamic new material that would markedly enhance the healing of soldiers who suffer traumatic wounds in the field of battle. These wounds often lead to secondary fractures and infections, multiple surgeries, long rehabilitation times and, in some cases, amputation. "Fracture putty represents the ultimate convergence of orthopedic material science and mechanics, and has the potential to revolutionize the way patients are treated," said DARPA's program manager, Mitchell Zakin, PhD. "If all technical challenges are met, we believe this innovative technology will provide superior clinical outcomes for patients."

Sign up for the free TryPennyStocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

About TryPennyStocks

TryPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer.